The fact that ER−/PR+/HER2-patients were younger at the time of diagnosis like ER+/PR any and HER2+, with high SBR grade III like TNBC HER2+, high tumor size and negative lymph node status like TNBC, and that ER−/PR+/HER2+ patients were older at the time of diagnosis like TNBC, with high SBR grade differing from ER+/PR any, high tumor size but with positive lymph node status, reveals that ER−/PR+/HER2− and ER−/PR+ HER+ are distinct ER−/PR+ breast cancer phenotypes with distinct clinicopathological characteristics. The gene discussed is PGR; the disease is breast cancer.